GSE184593
Transcriptional behavior of regulatory T cells predicts IBD patient responses to vedolizumab therapy
Vedolizumab (VDZ) is used to treat patients with IBD but the exact way it works is not known. We studied the immune system in the blood and intestine of patients treated with VDZ and found immune characteristics that correlated with response. Overall design: Mucosal biopsies from UC and CD were digested for single cells and FAC sorted for Treg and Tmem subset  sorted from PBMCs and biopsies Total RNA sequencing of 940 samples